SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $30,926.52 in Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 2,439 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the sale, the chief financial officer now owns 194,623 shares in the company, valued at $2,467,819.64. This represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, September 3rd, Anshul Maheshwari sold 1,414 shares of SI-BONE stock. The shares were sold at an average price of $16.35, for a total transaction of $23,118.90.

SI-BONE Price Performance

Shares of SI-BONE stock traded down $0.17 on Wednesday, hitting $12.15. The company’s stock had a trading volume of 217,144 shares, compared to its average volume of 392,037. The company has a market capitalization of $509.57 million, a price-to-earnings ratio of -13.39 and a beta of 1.22. SI-BONE, Inc. has a 1 year low of $11.76 and a 1 year high of $21.70. The firm has a fifty day moving average price of $13.91 and a 200-day moving average price of $14.26. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Champlain Investment Partners LLC lifted its holdings in SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after purchasing an additional 358,821 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of SI-BONE by 1.8% in the first quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company’s stock valued at $40,328,000 after purchasing an additional 43,670 shares during the period. American Century Companies Inc. increased its position in SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares during the last quarter. Bellevue Group AG raised its stake in SI-BONE by 4.1% during the third quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock worth $20,189,000 after purchasing an additional 56,500 shares during the period. Finally, Paradigm Capital Management Inc. NY boosted its holdings in SI-BONE by 24.7% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock valued at $17,448,000 after purchasing an additional 267,100 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on SIBN shares. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a report on Wednesday. Morgan Stanley lowered their price objective on SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Finally, Truist Financial lifted their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.